Skip to main content

Advertisement

Fig. 1 | EJNMMI Research

Fig. 1

From: First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist 68Ga-NODAGA-MJ9

Fig. 1

Maximum intensity projections acquired 10, 45, 70 and 100 min after 68Ga-NODAGA-MJ9 injection (ad, respectively) in a 56-year-old patient with biochemical relapse of prostate cancer (patient #5). The typical 68Ga-NODAGA-MJ9 biodistribution is observed, including visualisation of the urinary system, as well as fast and prominent uptake by the pancreas and the biliary tract

Back to article page